Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Teclistamab in a large cohort of ~100 Asian patients with triple-class exposed multiple myeloma: Experience from trials and non-trial settings

Blood (2025) 146 (Supplement 1): 5815.

https://doi.org/10.1182/blood-2025-5815

Published: 2025

Journal Articles

A single-centre comparison of thiotepa-treosulfan versus thiotepa-busulfan based conditioning regimens in adults with haematological malignancies undergoing allogeneic haematopoietic stem cell transplant.

Kye Ling Wong, Tze Wei Chan, Chieh Hwee Ang, Tertius Tuy, Hein Than, Melinda Si Yun Tan, Lawrence Ng, Shin Ong, Yunxin Chen, Francesca Lim, Chandramouli Nagarajan, William Hwang, Yeow Tee Goh, Yeh-Ching Linn, Aloysius Ho, Jeffrey Quek

Blood (2025) 146 (Supplement 1): 5982.

https://doi.org/10.1182/blood-2025-5982

Published: 2025

Journal Articles

Short survival with BCMA and GPRC5D dual antigen exposed relapsed myeloma- an international myeloma working group immunotherapy database analysis

Blood (2025) 146 (Supplement 1): 4598.

https://doi.org/10.1182/blood-2025-4598

Published: 2025

Journal Articles

Phase I/II study of mezigdomide and elranatamab for relapsed/refractory multiple myeloma patients (MELT-MM): Initial results from part 1

Ja Min Byun, Chang-Ki Min, Kihyun Kim, Dok Hyun Yoon, Sung-Hoon Jung, Wee-Joo Chng, Chandramouli Nagarajan, Youngil Koh

Blood (2025) 146 (Supplement 1): 5835.

https://doi.org/10.1182/blood-2025-5835

Published: 2025

Journal Articles

Real world efficacy and safety of elranatamab, a BCMA bispecific antibody for patients with relapsed and refractory multiple myeloma: An international myeloma working group immunotherapy database analysis

Blood (2025) 146 (Supplement 1): 4588.

https://doi.org/10.1182/blood-2025-4588

Published: 2025

Journal Articles

Outcome of Extra-Nodal Follicular Lymphoma Affected By Selection of Induction Chemoimmunotherapy and Maintenance Rituximab - Real-World Retrospective Study

Blood (2024) 144 (Supplement 1): 6277.

https://doi.org/10.1182/blood-2024-193417

Published: 2024

Journal Articles

Machine Learning Classification of Spatial Patterns of Malignant Cells Reveals Implications in Prognosis and Tumor Microenvironment Composition in Lymphoma

Blood (2024) 144 (Supplement 1): 3602.

https://doi.org/10.1182/blood-2024-209372

Published: 2024

Journal Articles

Outcomes of Autologous Stem Cell Transplant in Primary and Secondary Central Nervous System Lymphoma - a Multi Center Experience in Singapore

Blood (2024) 144 (Supplement 1): 6467.

https://doi.org/10.1182/blood-2024-205120

Published: 2024

Journal Articles

The Endothelial Activation and Stress Index (EASIX) Score Improves Risk Stratification for Double Expressor Diffuse Large B-Cell Lymphoma (DEL)

Jing Yuan Tan, Jason Yongsheng Chan, Shin Yeu Ong, Chandramouli Nagarajan, Yunxin Chen, Francesca Lorraine Wei Inng Lim, Nicholas Francis Grigoropoulos, Ya Hwee Tan, Joshua Tian Ming Hoe, Jianbang Chiang, Esther Chang, Eileen Poon, Nagavalli Somasundaram, Miriam Tao, Yeow Tee Goh, Soon Thye Lim, Lawrence Cheng Kiat Ng

Blood (2024) 144 (Supplement 1): 6450.

https://doi.org/10.1182/blood-2024-194684

Published: 2024

Journal Articles

Importance of Fluorescence in Situ Hybridization (FISH) Analysis on Bone Core Specimen for Detection of Relapse in Myeloid Malignancies with Fibrosis

Lee Voon Chu, Tse Hui Lim, Hein Than, Sim Leng Tien, Soon Tiong Alvin Lim, Lai Ching Lau, Aloysius Yew Leng Ho, Jeffrey Kim Siang Quek, Francesca Lorraine Wei Inng Lim, Yunxin Chen, William Ying Khee Hwang, Chandramouli Nagarajan, Lawrence Cheng Kiat Ng, Melinda Si Yun Tan, Tertius Tansloan Tuy, Chieh Hwee Ang, Yeh Ching Linn

Blood (2024) 144 (Supplement 1): 6096.

https://doi.org/10.1182/blood-2024-202353

Published: 2024

Journal Articles

Imaging Practices in Patients with Plasma Cell Dyscrasias across the Asian Myeloma Network - Survey Results and Recommendations

Natasha Fay Anthony, Wenming Chen, Chim James, Gin Gin Gan, Jeffrey Huang, Kihyun Kim, Teeraya Puavilai, Wee-Joo Chng, Kazuyuki Shimizu, Brian GM Durie, Chandramouli Nagarajan

Blood (2023) 142 (Supplement 1): 6666.

https://doi.org/10.1182/blood-2023-173228

Published: 2023

Journal Articles

Daratumumab Bortezomib and Dexamethasone in Transplant Ineligible Newly Diagnosed Elderly Myeloma Patients - a Trial By Asian Myeloma Network

Chandramouli Nagarajan, Melinda Tan, Yunxin Chen, Melissa Ooi, Sanjay De Mel, Allison Tso, Lawrence Ng, Hein Than, Yeow Tee Goh, Brian GM Durie, Wee-Joo Chng

Blood (2023) 142 (Supplement 1): 6721.

https://doi.org/10.1182/blood-2023-173476

Published: 2023

Journal Articles

Co-Expression of C-MYC/BCL2 Is Associated with Inferior Survival Outcomes in Relapsed/Refractory Diffuse Large B-Cell Lymphoma after Autologous Stem Cell Transplantation - a Nationwide Retrospective Analysis in Singapore

Blood (2023) 142 (Supplement 1): 3601.

https://doi.org/10.1182/blood-2023-184423

Published: 2023

Journal Articles

Single Cell Profiling Unravels Plasma Cell Gene Expression Signatures Predictive of Response to Daratumumab Based Therapy, and Prognosis in Multiple Myeloma

Jonathan Scolnick, Stacy Xu, Cinnie Soekojo, Fangfang Song, Melissa Ooi, Chandramouli Nagarajan, Wee-Joo Chng, Sanjay De Mel

Blood (2023) 142 (Supplement 1): 3367.

https://doi.org/10.1182/blood-2023-182805

Published: 2023

Journal Articles

Carfilzomib Use Among Patients with Relapsed/Refractory Multiple Myeloma in the Asia Pacific Region: Characteristics and Outcomes By Regimen from a Prospective, Real-World Study

Hang Quach, Sung-Soo Yoon, Kihyun Kim, Ji Hyun Lee, Chandramouli Nagarajan, Phoebe Joy Ho, Michael S.Y. Low, Wei-Han Huang, Raymond Wong, Nina Liao, ChingFeng Lin, Matthew Britland, Julia Li, Stella Chai, Jin Seok Kim

Blood (2022) 140 (Supplement 1): 4264–4266.

https://doi.org/10.1182/blood-2022-159324

Published: 2022

Journal Articles

Daratumumab in Multiple Myeloma - a Nationwide Real-World Experience from Singapore

Allison Ching Yee Tso, Wee Joo Chng, Yeow Tee Goh, Melissa Ooi, Yunxin Chen, Chandramouli Nagarajan, Daryl Tan, Kiat Hoe Ong

Blood (2022) 140 (Supplement 1): 12596–12597.

https://doi.org/10.1182/blood-2022-157940

Published: 2022

Journal Articles

Real-World Outcomes of Patients with Primary CNS Lymphoma (PCNSL): A Report from the Australasian Lymphoma Alliance (ALA)

Blood (2021) 138 (Supplement 1): 2532.

https://doi.org/10.1182/blood-2021-145959

Published: 2021

Journal Articles

Ambiguous Diagnosis of Nodal T-Cell Lymphomas with T-Follicular Helper (TFH) Phenotype and Hodgkin Lymphoma - a Multicenter Pilot Study

Blood (2021) 138 (Supplement 1): 1403.

https://doi.org/10.1182/blood-2021-149358

Published: 2021

Journal Articles

Phase I/II Dose-Escalation Study of Lenalidomide in Combination with R-GDP for Treatment of Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Followed By Maintenance Lenalidomide

Colin Phipps, MD, Chandramouli Nagarajan, MBBS, Lawrence Ng, MBBS, Jane L Chua, Yunxin Chen, MBBS, Shin Yeu Ong, MD, Melinda Si Yun Tan, MBBS, Nicholas Francis Grigoropoulos, MD PhD, Sathish Gopalakrishnan, MD, Heng Joo Ng, MBBS, William YK Hwang, MBBS, Yeow Tee Goh, MBBS, Yuh Shan Lee, MBBS

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-142275

Published: 2020

Journal Articles

Phase 2 Study of Daratumumab in Combination with Thalidomide and Dexamethasone in Asian Patients with Relapsed/Refractory Myeloma (RRMM) - Interim Analysis of a Trial By the Asian Myeloma Network (AMN)

Wee-Joo Chng, MBBS, PhD FRCPath, FRCP, Cindy Lin, Xinhua Li, Chandramouli Nagarajan, MBBS, Sung-Soo Yoon, MD PhD, Brian G.M. Durie, MD

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-139092

Published: 2020

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Teclistamab in a large cohort of ~100 Asian patients with triple-class exposed multiple myeloma: Experience from trials and non-trial settings

A single-centre comparison of thiotepa-treosulfan versus thiotepa-busulfan based conditioning regimens in adults with haematological malignancies undergoing allogeneic haematopoietic stem cell transplant.

Short survival with BCMA and GPRC5D dual antigen exposed relapsed myeloma- an international myeloma working group immunotherapy database analysis

Phase I/II study of mezigdomide and elranatamab for relapsed/refractory multiple myeloma patients (MELT-MM): Initial results from part 1

Real world efficacy and safety of elranatamab, a BCMA bispecific antibody for patients with relapsed and refractory multiple myeloma: An international myeloma working group immunotherapy database analysis

Outcome of Extra-Nodal Follicular Lymphoma Affected By Selection of Induction Chemoimmunotherapy and Maintenance Rituximab - Real-World Retrospective Study

Machine Learning Classification of Spatial Patterns of Malignant Cells Reveals Implications in Prognosis and Tumor Microenvironment Composition in Lymphoma

Outcomes of Autologous Stem Cell Transplant in Primary and Secondary Central Nervous System Lymphoma - a Multi Center Experience in Singapore

The Endothelial Activation and Stress Index (EASIX) Score Improves Risk Stratification for Double Expressor Diffuse Large B-Cell Lymphoma (DEL)

Importance of Fluorescence in Situ Hybridization (FISH) Analysis on Bone Core Specimen for Detection of Relapse in Myeloid Malignancies with Fibrosis

Imaging Practices in Patients with Plasma Cell Dyscrasias across the Asian Myeloma Network - Survey Results and Recommendations

Daratumumab Bortezomib and Dexamethasone in Transplant Ineligible Newly Diagnosed Elderly Myeloma Patients - a Trial By Asian Myeloma Network

Co-Expression of C-MYC/BCL2 Is Associated with Inferior Survival Outcomes in Relapsed/Refractory Diffuse Large B-Cell Lymphoma after Autologous Stem Cell Transplantation - a Nationwide Retrospective Analysis in Singapore

Single Cell Profiling Unravels Plasma Cell Gene Expression Signatures Predictive of Response to Daratumumab Based Therapy, and Prognosis in Multiple Myeloma

Carfilzomib Use Among Patients with Relapsed/Refractory Multiple Myeloma in the Asia Pacific Region: Characteristics and Outcomes By Regimen from a Prospective, Real-World Study

Daratumumab in Multiple Myeloma - a Nationwide Real-World Experience from Singapore

Real-World Outcomes of Patients with Primary CNS Lymphoma (PCNSL): A Report from the Australasian Lymphoma Alliance (ALA)

Ambiguous Diagnosis of Nodal T-Cell Lymphomas with T-Follicular Helper (TFH) Phenotype and Hodgkin Lymphoma - a Multicenter Pilot Study

Phase I/II Dose-Escalation Study of Lenalidomide in Combination with R-GDP for Treatment of Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Followed By Maintenance Lenalidomide

Phase 2 Study of Daratumumab in Combination with Thalidomide and Dexamethasone in Asian Patients with Relapsed/Refractory Myeloma (RRMM) - Interim Analysis of a Trial By the Asian Myeloma Network (AMN)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only